Calendar

Rundown of all the drugs approved in 2022 with detailed analysis: why it matters for patients, the companies that brought them to market, and more.

90% of drugs fail in development. We take a look at the stumbles, blow-ups and near-misses of the experimental drugs that didn't make the cut.

The biggest biopharma industry conference of the year. A three-day event hosted by Endpoints alongside coverage of JPM: Wall-to-wall news stories, coverage via our event in San Francisco featuring in-person and online panels on the upcoming trends in biopharma with a focus on dealmaking, regulation coming from Washington, drug pricing, pipelines and more.

All the news from the biggest healthcare investor conference of the year — covered by the Endpoints team in real time.

What do analysts project to be the next big blockbuster products coming from R&D pipelines? Last year, this report highlighted the industry's biggest gamble — Biogen's Alzheimer's drug aducanumab. While the drug ended in failure, the story was one of the industry's biggest conversations all year.

The biopharma VC world's most prolific dealmakers, ranked by number of deals and the dollars they put to work. Featuring an interactive data set.

By all accounts, 2022 was a gut-wrenching year for biotech investors. The IPO window closed, after years of a free-for-all, and funding requirements grew bigger and longer for startups while valuations changed. So what did we learn about rounds and technology after crunching the numbers on one of the most popular lists at Endpoints News? Join editor-in-chief John Carroll and his panel of VC insiders for a round-table discussion about what lies ahead for biotech.

The next class of mRNA tech is poised to provide for a wide range of applications — but what exactly does the immediate future hold? Our expert panel will break down the latest mRNA products in development and find out where the technology is headed.

All the news out of the American College of Cardiology annual meeting, covered by the Endpoints team in real time.

Our semi-annual survey of CEOs & industry executives highlighting what’s top of mind for these leaders during the first half of the year. We survey our exclusive group, analyze their comments and use it to share where insiders think the industry is headed and what it cares about most.

R&D is the lifeblood of biopharma, but it doesn't come cheap. We break down the biggest spenders on research and development, and look at what they got in return for the bets they put on the table. Data and analysis of the industry's most important investment.

Last fall at ESC it became apparent that big cardio diseases are back in vogue. Merck’s picked up on this by making cardio a top growth sector in the pipeline. And we’ve been seeing a surge in new R&D projects. All this after big costs and low success rates forced a rethink in Big Pharma. What’s happening now to inspire such a big change? Lei Lei Wu is digging in.

Last fall at ESC it became apparent that big cardio diseases are back in vogue. Merck’s picked up on this by making cardio a top growth sector in the pipeline. And we’ve been seeing a surge in new R&D projects. All this after big costs and low success rates forced a rethink in Big Pharma. What’s happening now to inspire such a big change? Lei Lei Wu is digging in.

All the news from the American Association for Cancer Research conference in Orlando, Florida. This is an R&D-focused conference that always generates a handful of major headlines on the drugs of tomorrow.

The top news out of AACR delivered to our audience in a single email issue.

An Endpoints Day focused on drug discovery, featuring a panel session hosted by an Endpoints journalist with more sessions to be announced. This event will focus on research pipelines, emerging drug targets and the inflection point of research to development.

The people who turn drugs into blockbusters: Endpoints profiles the marketing leaders with the most influence in the industry.

Ever since the first oncolytic virus was approved way back in 2015, developers have been rushing ahead what they believed were sure-fire ways to create an effective wave of next-gen therapies that would be much, much better. But the promised never has yet to happen. Can this latest round of efforts beat the odds?

Ever since the first oncolytic virus was approved way back in 2015, developers have been rushing ahead what they believed were sure-fire ways to create an effective wave of next-gen therapies that would be much, much better. But the promised never has yet to happen. Can this latest round of efforts beat the odds?

Who made the biggest gambles with their M&A bets? This data-driven list looks at the biggest deals on experimental products that could turn into booms or busts.

The cell & gene landscape is ripe with big promises backed by evolving tech, fresh talent with splashes of funding and M&A catching headlines as therapies roll forward. But how are the experts doing it in 2023? What are the biggest scientific advancements — and best strategies for investment, manufacturing and commercial access? Join us as we explore the field’s future — and examine past safety issues — with a series of sessions geared toward furthering cell & gene drug development.

Our special report profiles the achievements of LGBTQ+ biopharma execs and scientific leaders who are influencing the industry.

The future leaders of biotech — many of whom are already reaching for the top of their game. These are the 20 executives under 40 who are making an impact on the industry, have raised serious capital, or are moving innovative, exciting companies forward.

A preview of what’s to come at BIO, delivered to our audience in a single email issue.

The most anticipated cancer conference of the year, with practice-changing clinical data and a large corporate presence eyeing one of the biggest categories of drug R&D and commercial sales. We have a team on the ground covering the hottest news out of ASCO.

ASCO never fails to make its mark as the oncology conference to watch, no matter which way the data are. What pipelines are going to swell — or fade — as the readouts surface? Is a reshaping of the cancer landscape in the cards this year or will slow and steady win the race? Join Endpoints News’ ASCO experts panel to recap the data you don’t want to miss — and more.

The top news out of ASCO delivered to our audience in a single email issue.

Our special report profiles the achievements of LGBTQ+ biopharma execs and scientific leaders who are influencing the industry.

The biotech industry's annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma. Featuring conversations with VCs and a focus on what the mid-year outlook holds.

Cannes has become one of the big hub events for media, marketing and advertising. We report on the marketing deals and trends that will drive how drugs are advertised and sold to patients.

Topic details coming soon

Topic details coming soon

The top news out of Cannes Lions delivered to our marketing audience in a single email issue.

The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.

90% of drugs fail in development. We take a look at the stumbles, blow-ups and near-misses of the drugs that didn't make the cut.

An Endpoints Day focused on drug commercialization, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. This event will focus on trends in drug launches, marketing and sales.

Who are the women leading and influencing biopharma? Each year we seek out the up-and-comers moving the industry forward. Our in-depth profiles establish their stories into the fabric of an industry that isn’t changing fast enough to keep up with gender diversity.

A spotlight on the women leading and influencing biopharma in 2023. Join us as we bring the award celebration to a live audience. We’ll gather a group of industry leaders to discuss the way forward to push gender equality to reality.

Topic details coming soon

As science has enabled care for previously untreatable, ultra-rare conditions, health systems and governments are struggling with ways of financing research and development of these therapies. What are the solutions when the science has progressed, but the economics haven't?

The pandemic spotlight on the world of manufacturing shifted the sector into a radical reality. Now that the world has moved forward — how has the new landscape affected the industry? From supply chain drain to capital expenditure hurdles, how exactly do we scale up and out? Join Endpoints for our first manufacturing day to find out what the experts are saying about the unique environment we are facing today.

Topic details coming soon

UC San Diego recently launched a new astrobiotechnology hub, but one of the efforts pushing drug development and manufacturing into space. After early experiments, researchers are now launching into the cosmos with more tangible aims, like refining drug targets and building better manufacturing technology.

The European Society of Cardiology — practice-changing research is revealed along with clinical updates to drugs in development. Endpoints is there in person covering the news as it breaks real time in Amsterdam.

Our semi-annual survey of CEOs & industry executives highlighting what’s top of mind for these leaders during the first half of the year. We survey our exclusive group, analyze their comments and use it to share where insiders think the industry is headed and what it cares about most.

Profiles of the top 11 private biotechs in pursuit of new drugs and who are pushing the envelope with powerful new technologies.

We’re back with another look at eleven of the most promising biotechs in the global industry. You can expect to see some great science, outstanding leadership and backers that are prepared to go the distance in one of the riskiest endeavors on the planet. They may not all make the finish line for success, but it won’t be for lack of trying. And we’ll be watching every step.

Topic details coming soon

Drug research institutes hatch early-stage research, but now they're drug pushing programs further into development, forming nonprofits to accelerate research and striking more complex financial deals. This webinar will examine the forces driving the focus on finances and some of the more novel approaches.

Where is cancer drug R&D is headed now — what are the new types of tech and targets making waves? What’s on the horizon for the latest cancer drugs in development?

What’s in store for the future of R&D in Europe? We’re charting the waters ahead this year and beyond — covering drug development, financing trends, regulatory issues and more on topics central to the biopharma industry. Our two-day hybrid event will be held live at the Financial Times headquarters in London — join us in person or tune in virtually. Access sessions covering the latest on the VC landscape, dealmaking in Europe and one-on-one chats featuring industry leader interviews by our journalists.

Europe’s headlining cancer conference lands in Madrid this year as major medical updates on drugs in the pipeline are given out. Endpoints covers the readouts in real time.

The top news out of ESMO delivered to our audience in a single email issue.

Our event on the ground at ESMO — we break down what drugs in the cancer pipeline are the ones to watch, and which ones didn’t make it past the goal line. Join our expert panel, fireside chat and more.

CPhI brings together members of the drug supply chain, including many of the critical pharma service companies that drive the supply and production of drugs. We cover it this year via our weekly Manufacturing Report.

The top news out of CPhI delivered to our manufacturing audience in a single email issue.

Topic details coming soon

Topic details coming soon

An Endpoints Day focused on clinical trials, featuring a panel session hosted by an Endpoints journalist and more. What are the latest trends in clinical trials? What regulatory curves are making the biggest waves? We’ll also take a look at how expectations from the industry and beyond are shifting the trial strategies of the future.

The 10 stories that Endpoints readers connected with most in 2023. They're the stories with the biggest impact, the largest readership, and that were key milestones for where the industry went this year.

Topic details coming soon

Topic details coming soon

The Endpoints team will be on the ground to bring drug updates out of ASH this year — will some of the most coveted cell & gene therapy readouts take center stage?

ASH’s focus on blood cancers and disorders provide the battleground for some of the most coveted cell & gene therapy readouts. The Endpoints team will take apart and piece together the data with a panel of experts followed by a fireside chat.

The top news out of ASH delivered to our audience in a single email issue.